CJC-1295 + Ipamorelin: evidence, identity, and blend-quality checks

CJC-1295 + Ipamorelin is a common GH-axis research blend, but the commercial name hides two separate procurement questions: which CJC material is actually present, and what evidence supports the finished combination rather than either component alone.

This guide separates published component-level evidence from blend-level assumptions. It is written for qualified research and procurement teams, not as a dosing, compounding, or clinical-use protocol.

Start with the evidence boundary

Human studies have evaluated long-acting DAC-linked CJC-1295 and Ipamorelin separately. Published CJC-1295 studies reported sustained GH and IGF-I changes after the DAC-linked material, while a human Ipamorelin study characterized its pharmacokinetic and GH-response profile.

Those studies support the component-level pathway rationale. They do not establish a clinically validated fixed-ratio CJC-1295 (no DAC) + Ipamorelin product, a universal ratio, or a predictable multiplication of GH response for the commercial blend. Procurement documents should not turn a mechanistic hypothesis into a measured finished-product claim.

Verify what “CJC-1295” means

The name CJC-1295 is used inconsistently in supplier catalogs:

• DAC-linked CJC-1295 is the long-acting material evaluated in the cited human CJC studies.
• “CJC-1295 no DAC” usually refers to Modified GRF 1-29, a different short-acting GHRH-receptor agonist without the drug-affinity-complex group.

A purchase specification should state the full sequence, modification state, expected molecular mass, counter-ion, and whether a DAC group is present. A label that says only “CJC-1295” is not sufficient identity control.

Why the two components are paired

CJC-class GHRH analogs act through the GHRH receptor. Ipamorelin is a growth-hormone secretagogue receptor agonist, and its human PK/PD study documented an episodic GH response after Ipamorelin exposure. The two receptor pathways provide the mechanistic reason researchers study them together.

That rationale is not a substitute for a direct study of the exact co-lyophilized formulation. Buyers should ask whether any blend-specific potency, stability, or ratio-recovery work was performed on the offered lot.

Treat the ratio as a manufacturing specification

Commercial blends are often offered at 1:1 nominal mass, such as 5 mg + 5 mg. That is a packaging convention, not evidence that the two components have equivalent receptor activity per milligram or that one ratio is appropriate for every study.

The written purchase specification should define:

• target mass of each component per vial
• acceptable assay range for each component
• the validated method used to resolve and quantify both peptides
• how ratio recovery and total content are calculated
• what happens when one component passes total-content testing but falls outside its individual assay range

Custom ratios should be buyer-defined against a documented research requirement, not inferred from catalog marketing.

Co-lyophilized blend release checks

A co-lyophilized presentation can simplify inventory and preserve a fixed manufacturing ratio, but only if the release method can distinguish the two components. Total peptide mass alone cannot prove component identity or ratio.

For the offered lot, request:

• identity evidence for both components, including expected mass and modification state
• a chromatographic method capable of separating and quantifying both peptides
• individual assay or content result for each component, not only combined mass
• actual recovered ratio and the approved acceptance range
• water content, counter-ion information, appearance, and container-closure details
• endotoxin, microbial, sterility, or other testing only when it is included in the written order scope and appropriate to the buyer's intended regulated workflow
• lot-specific stability evidence for the actual formulation and container

Handling must be lot-specific

Generic web instructions cannot replace the released lot's written storage and handling documents. Diluent choice, reconstituted hold time, freeze-thaw allowance, and retest period depend on formulation, container, method, and stability data.

Before quotation, specify any required stability condition, in-use study, analytical method, reporting format, and acceptance criterion. PeptideXpo confirms only the tests and results actually included for the offered or supplied lot.

Qualification questions for suppliers

• Does “CJC-1295” mean DAC-linked CJC-1295 or Modified GRF 1-29?
• Can the batch method resolve both peptide peaks and report each assay separately?
• Is the displayed ratio nominal input, recovered analytical ratio, or both?
• Was stability assessed on the exact co-lyophilized formulation and closure?
• Which additional tests are complete, and which are optional buyer-funded work?